

Kathleen W Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4805397/publications.pdf>

Version: 2024-02-01

19
papers

159
citations

1478505

6
h-index

1199594

12
g-index

19
all docs

19
docs citations

19
times ranked

199
citing authors

#	ARTICLE	IF	CITATIONS
1	Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis. JACC Basic To Translational Science, 2019, 4, 438-448.	4.1	38
2	Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy. International Journal of Cardiology, 2021, 322, 177-182.	1.7	18
3	Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). Journal of Urology, 2021, 206, 613-622.	0.4	18
4	Echocardiographic and clinical predictors of cardiac amyloidosis: limitations of apical sparing. ESC Heart Failure, 2022, 9, 385-397.	3.1	18
5	Cardiac Biomarkers During Cancer Therapy. JACC: CardioOncology, 2020, 2, 791-794.	4.0	11
6	Plasma Hepatocyte Growth Factor for Diagnosis and Prognosis in Light Chain and Transthyretin Cardiac Amyloidosis. JACC: CardioOncology, 2020, 2, 56-66.	4.0	10
7	Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma. Clinical Cancer Research, 2021, 27, 3854-3860.	7.0	9
8	Unsupervised cluster analysis of patients with recovered left ventricular ejection fraction identifies unique clinical phenotypes. PLoS ONE, 2021, 16, e0248317.	2.5	8
9	Coronary heart disease and mortality following a breast cancer diagnosis. BMC Medical Informatics and Decision Making, 2020, 20, 88.	3.0	7
10	Cardiac Amyloidosis for the Primary Care Provider: A Practical Review to Promote Earlier Recognition of Disease. American Journal of Medicine, 2021, 134, 587-595.	1.5	5
11	A multi-modal diagnostic model improves detection of cardiac amyloidosis among patients with diagnostic confirmation by cardiac biopsy. American Heart Journal, 2021, 232, 137-145.	2.7	4
12	Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients. International Journal of Cardiovascular Imaging, 2021, 37, 3003-3017.	1.5	4
13	Developing Therapy for Transthyretin Amyloidosis. American Journal of Medicine, 2022, , .	1.5	4
14	Apical Sparing Pattern of Longitudinal Strain and Positive Bone Scintigraphy in Metastatic Myocardial Calcification. JACC: Case Reports, 2020, 2, 809-813.	0.6	2
15	Out of the woods, but still in the weeds: When cancer therapy becomes part of a chronic condition. Heart, 2021, 107, 607-608.	2.9	1
16	Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). Reply.. Journal of Urology, 2022, 207, 243-243.	0.4	1
17	Towards improving clinical and patient-centred outcomes in patients with light chain amyloidosis. Heart, 2022, 108, 1586-1587.	2.9	1
18	Cardiac Amyloidosis. JACC: CardioOncology, 2020, 2, 719-720.	4.0	0

#	ARTICLE	IF	CITATIONS
19	Introduction to “Proceedings from Amyloidosis, A Hidden Disease with a Bright Future: A Multi-Disciplinary Approach to Diagnosis and Management of Amyloidosis” American Journal of Medicine, 2022, , .	1.5	0